New liver stent aims to tame deadly cirrhosis complications

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. The subject who is 18 years old or above but 75 years old or below; 2. The subject who is diagnosed with portal hypertension caused by liver cirrhosis with the history of gastrointestinal variceal bleeding or bleeding, hepatic hydrothorax, and refractory or recurrent ascites; 3. The subject must have adequate functional hepatic reserve with a Model for End-Stage Liver Disease (MELD) Score of ≤13 or Child-Pugh Score of ≤18; 4. The subject with platelet count≥ 20×10\^9 /L; 5. Subjects or their guardians who can understand the content of the clinical trial, voluntarily participate in the clinical trial and sign the ICF and can complete the follow-up period according to the requirements of the clinical trial. Exclusion Criteria: 1. The subject who is pregnant or lactating or plan to get pregnant during the clinical trial; 2. According to the judgment of investigator, the subject with main portal vein thrombosis which thrombus occupying \>50% of the portal vein lumen and affecting postoperative hemodynamics; 3. The subject who has received surgical or interventional treatment (such as TIPS, surgical shunt and retrograde transvenous obliteration (-RTO) for treatment of complications from portal hypertension. Note: The subject who have received -RTO for variceal bleeding at least 8 weeks before signing the informed consent form can be included in the clinical trial; 4. The subject who needs to receive or have received splenectomy; 5. The subject who has received or plan to receive liver transplantation; 6. The subject who cannot have a shunt channel established in the liver parenchyma between the hepatic vein and the portal vein as determined by the investigators; 7. The subject with extrahepatic or hepatic malignancies; 8. The subject with Budd-Chiari syndrome and hepatic sinusoidal obstruction syndrome; 9. The subject with congenital cystic dilatation of bile duct (Caroli disease) and obstructive dilation of biliary tract; 10. The subject with polycystic liver disease; 11. The subject with cavernous transformation of the portal vein; 12. The subject with severe or refractory hepatic encephalopathy (Grade 2 or above according to the West Haven Criteria); 13. The subject with a TBIL level higher than 51.3 μmol/L (excluding the Patients with cholestatic cirrhosis); 14. The subject with coagulation disorders (INR: \>2.5); 15. The subject with a systolic pressure lower than 80 mmHg; 16. The subject with severe tricuspid regurgitation or congestive heart failure; 17. The subject with myocardial infarction within the past 3 months; 18. The subject with moderate to severe pulmonary arterial hypertension, or severe hepatopulmonary syndrome; 19. The subject with uncontrolled systemic infection or inflammation; 20. The subject with severe renal insufficiency (Scr level:\>199.5 μmol/L) or needing to receive dialysis; 21. The subject known to be allergic to the contrast media or to the constituent materials of the TIPS covered segment; 22. The subject with the history of epilepsy or mental illness or with cognitive impairment; 23. The subject with the expected survival time of less than 1 year; 24. The subject who is otherwise determined as ineligible for participation in this Study by investigators; 25. The subject who is participating in any other unfinished drug or medical device clinical trials.